DECISION OF THE EEA JOINT COMMITTEE No 303/2022

of 9 December 2022

amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2023/1245]

THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (“the EEA Agreement”), and in particular Article 98 thereof,

Whereas:

(1) Commission Delegated Regulation (EU) 2022/1518 of 29 March 2022 amending Regulation (EC) No 273/2004 of the European Parliament and of the Council and Council Regulation (EC) No 111/2005 as regards the inclusion of certain drug precursors in the list of scheduled substances  ( 1 ) is to be incorporated into the EEA Agreement.

(2) Annex II to the EEA Agreement should therefore be amended accordingly,

HAS ADOPTED THIS DECISION:

Article 1

The following indent is added in point 15x (Regulation (EC) No 273/2004 of the European Parliament and of the Council) of Chapter XIII of Annex II to the EEA Agreement:

‘-

32022 R 1518 : Commission Delegated Regulation (EU) 2022/1518 of 29 March 2022 ( OJ L 236, 13.9.2022, p. 1 ).’

Article 2

The text of Delegated Regulation (EU) 2022/1518 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union , shall be authentic.

Article 3

This Decision shall enter into force on 10 December 2022, provided that all the notifications under Article 103(1) of the EEA Agreement have been made  ( *1 ) .

Article 4

This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union .

Done at Brussels, 9 December 2022.

For the EEA Joint Committee

The President

Kristján Andri STEFÁNSSON

( 1 )    OJ L 236, 13.9.2022, p. 1 .

( *1 )   No constitutional requirements indicated.